Listen to article
6:13Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 16 October 2026
Read article
Every so often, the market gets a sharp, necessary slap in the face. It’s a moment that cuts through the hype and forces everyone to ask some rather uncomfortable questions. To me, the US Food and Drug Administration’s recent decision to issue its strongest possible warning on a major cancer therapy feels like one of those moments. It’s a regulatory shot across the bow, and for investors who have been piling into the oncology space, it might be time to check the map.
Let’s be clear. The therapy in question, Carvykti, from the giants Johnson & Johnson and their partner Legend Biotech, was meant to be a game-changer. The technology, known as CAR-T, involves taking a patient’s own immune cells, giving them a bit of a tune-up in a lab, and sending them back in to fight the cancer. It sounds like something from science fiction, and for a while, it was treated with the same breathless optimism.
But when a regulator issues a "boxed warning", it’s the equivalent of a teacher calling your parents. It signals serious, potentially life-threatening risks. This isn’t just a minor hiccup. For a behemoth like Johnson & Johnson, it’s a costly headache. For a smaller firm like Legend Biotech, whose fortunes are more tightly tethered to this one product, it could be an existential threat. It seems the revolutionary promise of CAR-T might come with a rather nasty sting in its tail.
If the reigning champion of cancer treatment is looking a bit wobbly, where should a savvy investor look next? Well, it seems the attention is shifting towards the less glamorous, but perhaps more reliable, alternatives. Think of them as the sensible cousins of the flashy CAR-T therapies.
Two areas in particular are catching my eye. First, you have antibody-drug conjugates, or ADCs. In simple terms, these are like guided missiles. They use an antibody to find the cancer cells and then deliver a payload of chemotherapy directly to the target, sparing many of the healthy cells. It’s a more precise, less chaotic approach. Then there are Natural Killer, or NK, cell therapies, which use the body’s own innate immune cells without the need for complex genetic modification. The thinking here is that they might offer similar firepower with fewer safety concerns. This is a theme captured well by investment baskets like the Alternative Cancer Therapies Focus Shifts 2025, which are built on this very premise of a changing of the guard.
Now, before you rush off and remortgage your house to pile into biotech minnows, a word of caution. Investing in this sector is not for the faint of heart. It is a brutal, unforgiving landscape where nine out of ten promising ideas end up on the scrapheap of failed clinical trials. Regulatory approval is never a given, and even the most brilliant science can be undone by a poorly designed study or a competitor getting to market first.
This FDA warning doesn’t automatically mean that every CAR-T company is doomed, nor does it guarantee that every ADC developer will succeed. What it does signal, however, is a fundamental shift in priorities. The market, and more importantly the regulators, are now weighing safety just as heavily as effectiveness. Companies that can deliver both might just find themselves in a very powerful position indeed. For investors, the game has changed. The question is no longer just "does it work?", but "at what cost?".
View the full Basket:Alternative Cancer Therapies Focus Shifts 2025
View the full Basket:Alternative Cancer Therapies Focus Shifts 2025
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 16 October 2026
Read article
